Innate Pharma Announces Virtual Key Opinion Leader Event On Lacutamab, A First-In-Class Anti-KIR3DL2 Antibody Currently In Development For Cutaneous T-Cell Lymphoma And Peripheral T Cell Lymphoma
Portfolio Pulse from Benzinga Newsdesk
Innate Pharma announced a virtual KOL event to discuss lacutamab, an anti-KIR3DL2 antibody for T-cell lymphoma. Positive results from the TELLOMAK Phase 2 Trial in Sézary syndrome patients will be presented at the ASH Annual Meeting. The event is scheduled for December 12, 2023.
November 27, 2023 | 6:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Innate Pharma is set to present positive Phase 2 trial results for lacutamab, potentially boosting investor confidence in the drug's prospects.
The announcement of positive trial results and the upcoming KOL event are likely to generate investor interest and optimism about lacutamab's future, potentially leading to a short-term increase in Innate Pharma's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100